Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
34 results about "Hypoxia response" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Another response to hypoxia is called vasodillation, wherein the blood vessels become wider to allow more blood and oxygen to circulate throughout the body. When blood vessels are dilated, muscles are also more relaxed, and blood pressure becomes lower.
Hypoxia response polymer nanoparticle and application thereof
ActiveCN108653288AImprove enrichment capacityImprove tumor treatment effectOrganic active ingredientsPowder deliveryTumor therapyDrug release
The invention relates to a hypoxia response polymer nanoparticle and application thereof. The method comprises the following steps: firstly crosslinking 4,4-diaminoazobenzene and terephthalaldehyde taken as monomers, so as to form a conjugated polymer link, loading a photosensitizer and chemotherapy drugs through noncovalent interaction, and then forming the hypoxia response polymer nanoparticle through a nanoprecipitation method. The hypoxia response polymer nanoparticle can successfully carry the photosensitizer and the chemotherapy drugs to tumor cells, and produce active oxygen during illumination, so as to realize tumor killing. Azo bonds contained in the nanoparticle can be degraded under the action of reductase in cells, and chemotherapy drug release is realized. In addition, cell hypoxia caused during a photodynamic therapy process can further improve drug release, and the hypoxia response polymer nanoparticle can properly realize excellent tumor therapy effect through combination therapy effect of photodynamic therapy and chemical therapy.
Owner:MENGCHAO HEPATOBILIARY HOSPITAL OF FUJIAN MEDICAL UNIV
Composition and methods for inhibiting expression of hypoxia-inducible genes
InactiveUS20060025429A1Reduce and inhibit expressionReducing and inhibiting angiogenesisBiocideGenetic material ingredientsHypoxia responseInducible gene
Methods are provided for interfering with a hypoxia-mediated transcriptional pathway using an agent that binds to a hypoxia response element and inhibits transcription of a hypoxia inducible gene associated therewith. Also provided are methods of treating a patient with a solid tumors, and compositions useful for treating a patient having solid tumors, including, for example, by administering an agent that binds to a hypoxia response element in a cell. Agents for the methods of the invention are provided including compositions comprising a pyrrole imidazole polyamide or a pharmaceutically acceptable salt or complex thereof.
Owner:CALIFORNIA INST OF TECH
Hypoxia response lipidosome drug carrier as well as preparation method and application thereof
ActiveCN106692059ANo characteristicNo leakagePharmaceutical non-active ingredientsAntineoplastic agentsDipalmitoyl PhosphatidylcholineDisease
The invention discloses a hypoxia response lipidosome drug carrier. The hypoxia response lipidosome drug carrier is prepared from phospholipid, cholesterol and hypoxia response molecules, wherein the mass ratio of the cholesterol to the phospholipid ranges from 1:10 to 1:2, and the mass ratio of the hypoxia response molecules to the phospholipid ranges from 1:10 to 1:4; the phospholipid is a mixture of dipalmitoyl phosphatidylcholine, dimyristoyl phosphatidylcholine and methoxy-polyethylene glycol-distearoyl phosphoethanolamine; the hypoxia response molecules are derivatives of a hydrophobic aromatic nitro compound and are located between bimolecular layers of the phospholipid. The hypoxia response lipidosome drug carrier disclosed by the invention is used for loading an antitumor drug, and has a remarkable effect in application to drugs for treating tumors or other hypoxia-related diseases.
Owner:北京华诺泰生物医药科技有限公司
Compounds, compositions and use for anticancer therapy
Cell plasma membrane impermeable compounds and compositions thereof used for anticancer treatment are provided. The compounds contain functional groups capable of blocking and / or inhibiting trans-plasma membrane electron transport (tPMET), cell surface respiration and uncoupling cell surface oxidative-phosphorylation. The compositions comprise at least one of the cell plasma membrane impermeable compounds in combination with compounds of multi-function inhibitor capable of inhibiting cancer cell hypoxia responses.
Owner:天津药和生物医药科技有限公司
Composition containing brassica rapa.L and ginseng and application of composition
The invention provides a composition and an application thereof. Specifically, the invention provides an anti-hypoxia composition, wherein the composition consists of a first active ingredient of brassica rapa.L or an effective component containing the brassica rapa.L and a second active ingredient of ginseng or an effective component containing the ginseng. According to the composition provided by the invention, through the combined application of the brassica rapa.L (or the active ingredient thereof) and the ginseng (or the active ingredient thereof), a quite significant synergistic effect is achieved, so that the tolerance of a body to a hypoxic environment is obviously enhanced and a hypoxia response is effectively relieved.
Owner:西藏宏发盛桃食品股份有限公司 +1
Nanoparticle releasing H2S under hypoxic condition as well as preparation method and application of nanoparticle
ActiveCN111643482AEasy to detectPlay a therapeutic effectNervous disorderAntipyreticHypoxia responseAqueous solubility
The invention discloses a nanoparticle releasing H2S under a hypoxic condition as well as a preparation method and application of the nanoparticle. The nanoparticle has uniform size, good stability and good dispersity in water. The nanoparticle contains a water-soluble H2S donor, a conjugated polymer with a hypoxia response effect, an aza-BODIPY dye with a photothermal effect and a coating material coating the three materials to form the nanoparticle. The nanoparticle has uniform size and good dispersity in water, can release the H2S in the hypoxic environment and solves the problems of poor solubility, low release rate of a traditional H2S donor and the like, so that the H2S has wider application in biological diagnosis and treatment of diseases.
Owner:NANJING UNIV OF POSTS & TELECOMM
Hypoxia response chiral medicament micelle for targeting triple-negative breast cancer and preparation method of hypoxia response chiral medicament micelle
ActiveCN111743861AImprove intake capacityEasy accessOrganic active ingredientsPharmaceutical non-active ingredientsAptamerPolyethylene glycol
The invention belongs to the technical field of nano-medicaments, and discloses a hypoxia response chiral medicament micelle for targeting triple-negative breast cancer and a preparation method of thehypoxia response chiral medicament micelle. The preparation method comprises the following steps: firstly, introducing an azobenzene group into a molecular chain of carboxyl polyethylene glycol active ester, and obtaining carboxyl polyethylene glycol azobenzene; then, preparing the carboxyl polyethylene glycol-azobenzene-dextrorotatory polylactic acid segmented copolymer through reaction with carboxyl dextrorotatory polylactic acid; then introducing an amino-modified aptamer AS1411 to prepare AS1411-modified polyethylene glycol-azobenzene-dextral polylactic acid, compounding a fat-soluble anti-cancer drug, and then dialyzing to obtain the micelle disclosed by the invention. The low-oxygen-response chiral medicament micelle provided by the invention is small in particle size and narrow indistribution, and can be effectively retained at a targeted part; low-oxygen responsiveness is achieved, and the effect of low-oxygen slow release is achieved; TNBC tumors can be targeted, anti-cancerdrugs are selectively released, and the anti-tumor effect is remarkably improved.
Owner:NANTONG UNIVERSITY
Intermittent low-pressure and low-oxygen rehabilitation physiotherapy cabin
InactiveCN113303999AGood treatment effectReduce the burden onBreathing protectionTreatment roomsMedical equipmentTherapeutic effect
The invention relates to the technical field of medical equipment, and especially relates to an intermittent low-pressure and low-oxygen rehabilitation physiotherapy cabin. The cabin comprises a cabin body, a cabin door installed on the cabin body, a gas inlet unit, a vacuum pump unit and a control system used for controlling the air inlet unit and the vacuum pump unit. The gas outlet end of the gas inlet unit is communicated with the cabin body, and the gas inlet end of the vacuum pump unit is communicated with the cabin body; and the intermittent low-pressure and low-oxygen rehabilitation physiotherapy cabin provided by the invention can perform intermittent low-pressure and low-oxygen alternation. Under the hypoxia condition, degradation of a hypoxia inducible factor-1 alpha (HIF-1alpha) is affected and is combined with an HIF-1beta subunit to form a dimer, then the dimer is combined with a hypoxia response element, transcription of hundreds of genes in cells is activated, and the hypoxia inducible factor-1 alpha (HIF-1alpha) has a treatment effect on various diseases such as depression, insomnia, dementia, autism and arthralgia.
Owner:柯峰
Lentiviral expression vector for inducing HPV16 E6/E7 gene expression under hypoxia conditions
ActiveCN107630039APromote differentiationAvoid immunogenic reactionsBlood/immune system cellsFermentationVirus typeRed blood cell
The invention discloses a lentiviral expression vector for inducing HPV16 E6 / E7 gene expression under hypoxia conditions. The lentiviral expression vector contains a hypoxia response element, a CMV-minimum promoter and a HPV16 E6 / E7 gene. The lentiviral expression vector can induce directional differentiation of hematopoietic stem cells into immortalized erythroid progenitor cells under the hypoxia conditions and the immortalized erythroid progenitor cells can differentiate into mature erythrocytes under normal oxygen supplying conditions. The erythrocytes induced by the vector has deformability and a oxygen bonding and release capability similar to those of the normal mature erythrocytes and has oxygen content of hemoglobin of 28+ / -2mmHg. The diameter of the erythrocyte injected into a mouse for 10min to 24h is decreased and the erythrocyte has a mature erythrocyte form in 24h and has good adaptability of existence in the body.
Owner:长春力太生物技术有限公司
Chromatin peptide for controlling expression of anoxic reaction gene through combining hypoxic response element
InactiveCN106366173AInhibition of energy acquisition pathwaysTo achieve the purpose of treatmentPeptide/protein ingredientsAntineoplastic agentsAnaerobic respirationCancer cell
The invention discloses a chromatin peptide. The chromatin peptide substantially is peptide oligomers formed by degradation of a transcription factor of a hypoxic response element in a human body cell anoxic reaction and biological bionic molecules of the peptide oligomers. The transcription factor of the hypoxic response element in malignant tumor cells starts anaerobic respiration in cells, cell proliferation, blood vessel formation and inflammations, and provides energy and space for further expansion of cancer cells. The chromatin peptide generated by the degradation of the transcription factors and the bionic molecules of the chromatin peptide can specifically stop the cell hypoxic response in order to inhibit energy obtaining approaches of the malignant tumor cells, so the malignant tumor cells can naturally grow old toward death in order to realize the treatment purpose.
Owner:北京京爱康科技有限公司
Urine detection method of platinum super-nanoparticles based on hypoxia response and application of urine detection method
PendingCN114137189AEfficient detectionHigh sensitivityChemical analysis using catalysisBiological testingDiseaseNanoparti cles
The invention discloses a urine detection method of platinum super-nanoparticles based on hypoxia response and application of the urine detection method. The platinum super-nano particle PNCA is formed by covalently connecting an aminated super-small platinum nano-cluster and 4, 4 '-dicarboxylic acid azobenzene azo with hypoxia response through an EDC / NHS reaction, and after the surface of the platinum super-nano particle PNCA is coated with a layer of hyaluronic acid HA, the nano particle can specifically target a tumor site. Afterwards, under the action of reductase in the hypoxic environment at the tumor site, the PNCA nanoparticles can be reduced and degraded into many small PtNCs to enter blood circulation again, and the PNCA nanoparticles can be excreted into urine from the kidney for disease state detection due to the fact that the particle size of the PNCA nanoparticles is smaller than the critical value 5.5 nm capable of being removed by the kidney. Due to the excellent hypoxia response effect of the PNCA nanoparticles and the efficient kidney clearing effect of the PtNCs, the PNCA / PtNCs composite material has obvious advantages in living body application.
Owner:NANJING UNIV
Anti-hypoxia and anti-fatigue food, health-care product or pharmaceutical composition, and preparation method and application thereof
PendingCN112617196ACompatibility is reasonableImprove oxygen resistanceOrganic active ingredientsSugar food ingredientsHypoxia responseDisease
The invention provides an anti-hypoxia and anti-fatigue food, health-care product or pharmaceutical composition, and a preparation method and application thereof. The composition is a food, health-care product or pharmaceutical preparation prepared from the following raw materials in parts by weight: 24-36 parts of ginseng, 80-120 parts of rhizoma polygonati, 16-24 parts of cordyceps militaris, 16-24 parts of albumin peptide, 16-24 parts of spirulina maxima, 16-24 parts of chia seeds, 16-24 parts of fructus lycii, 16-24 parts of sea buckthorn and 0.1-1 part of vitamin C. The composition disclosed by the invention is reasonable in compatibility, and plays a synergistic effect on fatigue resistance and oxidation resistance; the composition can also be used for relieving altitude stress and preventing acute and chronic altitude hypoxia diseases; meanwhile, the raw materials used in the composition disclosed by the invention are safe and free of toxic and side effects; safe and efficient energy supply can be provided; the endurance capacity of an organism to an anoxic environment is enhanced; symptoms, such as an anoxic reaction of the organism, are effectively relieved; and the composition has a good application prospect.
Owner:成都藏源高能生物科技有限公司
Nitroimidazole derivative for preparing hypoxic developer, preparation method and application thereof
ActiveCN113387927AIncreased sensitivityImproved ability to cross the blood-brain barrierIsotope introduction to heterocyclic compoundsRadioactive preparation carriersNitroimidazoleImaging agent
The invention provides a nitroimidazole derivative for preparing a hypoxic developer. The nitroimidazole derivative is selected from compounds with structural formulas as shown in a formula I, a formula II or a formula III, wherein R is C1-8 alkyl, saturated alkoxy or acylamino. The invention also provides a preparation method of the nitroimidazole compound and application of the nitroimidazole compound in preparation of a PET imaging agent. The nitroimidazole derivative provided by the invention has proper molecular weight and fat solubility, greatly improves the ability of an imaging agent to cross a blood brain barrier, and has higher sensitivity to hypoxia due to introduction of an azide hypoxia response group.
Owner:首都医科大学脑重大疾病研究中心
Hypoxia response co-assembly system based on extracellular vesicles and preparation method thereof
ActiveCN113831911AEfficient enrichmentLuminescence/biological staining preparationFluorescence/phosphorescenceExtracellular vesicleAluminum phthalocyanine
The invention relates to a co-assembly system based on extracellular vesicles and used for hypoxia response imaging. The co-assembly system comprises the extracellular vesicles and Pc / C5A attached to the extracellular vesicles, and the Pc / C5A contains calixarene QAC5A-6C and aluminum phthalocyanine AlPcS4. The method comprises the following steps: mixing calixarene QAC5A-6C (C5A) and aluminum phthalocyanine AlPcS4 (Pc), and carrying out first incubation to obtain Pc / C5A; and mixing with extracellular vesicles, and carrying out second incubation, so as to obtain the co-assembly system for hypoxia response imaging.
Owner:NANKAI UNIV
Hypoxia-responsive chiral drug micelles targeting triple-negative breast cancer and preparation methods thereof
ActiveCN111743861BImprove intake capacityEasy accessOrganic active ingredientsPharmaceutical non-active ingredientsPolythylene glycolAnti neoplastic
Owner:NANTONG UNIVERSITY
Hypoxia-responsive chimeric antigen receptors
PendingUS20220195009A1Reduction and substantial eliminationPeptide/protein ingredientsAntibody mimetics/scaffoldsAntigen receptorsHypoxia response
The present invention relates to therapeutic agents, particularly to therapeutic polypeptides and nucleic acids having the capacity for selective expression under conditions of hypoxia, cells incorporating the nucleic acids and their use in therapy, in particular in methods requiring selective expression under conditions of hypoxia, such as typically found in solid cancers. The nucleic acids encode novel hypoxia-responsive chimeric antigen receptors (CARs). The invention also relates to hypoxia-responsive regulatory nucleic acids.
Owner:KING'S COLLEGE LONDON
Compounds and methods for inhibiting cellular responses to hypoxia
InactiveUS7375132B2Reduce angiogenic growth factor productionHigh activityBiocideOrganic chemistryMedicineHypoxia-inducible factors
Owner:UNIVERSITY OF MISSISSIPPI
Lentiviral expression vector for inducing hpv16 E6/E7 gene expression under hypoxic conditions
ActiveCN107630039BPromote differentiationAvoid immunogenic reactionsBlood/immune system cellsFermentationMature erythrocyteErythroid cell
Owner:长春力太生物技术有限公司
Preparation method of angelica polysaccharide derivative for sensitizing ferroptosis through hypoxia response
ActiveCN113952466AAccelerated deathReduce concentrationOrganic active ingredientsPharmaceutical non-active ingredientsCancer cellSugar derivatives
The invention provides a preparation method of an angelica polysaccharide derivative for sensitizing ferroptosis through hypoxia response. The preparation method comprises the following steps: S1, carrying out synthesis of a carrier material: firstly, synthesizing angelica polysaccharide-azobenzoic acid, then synthesizing angelica polysaccharide-azobenzoic acid-ferrocene methanol, and finally, forming arachidonic acid-angelica polysaccharide-azobenzoic acid-ferrocene methanol; and S2, carrying out dialysis and freeze-drying treatment on the carrier material. According to the preparation method disclosed by the invention, by introduction of exogenous iron ferrocene, introduction of a ferroptosis precursor arachidonic acid and consumption of NADPH, which is caused by azobenzene bond degradation, ferroptosis is selectively sensitized, and cancer cell death is synergistically promoted. Reduction of azobenzene bonds involved in the preparation method disclosed by the invention causes a failure of the tumor NADPH, so that the concentration of intracellular GSH and Trx is reduced, the concentration of intracellular ROS is increased, and tumor cell ferroptosis is indirectly promoted. Based on liver targeting and passive targeting of angelica polysaccharide, the preparation method fulfills the aim of accurate tumor targeting drug delivery of the derivative.
Owner:济南天聚牧业科技有限公司
A kind of hypoxia responsive polymer nanoparticle and its application
ActiveCN108653288BThe synthesis steps are simple and mildReduce energy consumptionOrganic active ingredientsPowder deliveryTumor therapyTherapeutic effect
The invention relates to a hypoxia response polymer nanoparticle and application thereof. The method comprises the following steps: firstly crosslinking 4,4-diaminoazobenzene and terephthalaldehyde taken as monomers, so as to form a conjugated polymer link, loading a photosensitizer and chemotherapy drugs through noncovalent interaction, and then forming the hypoxia response polymer nanoparticle through a nanoprecipitation method. The hypoxia response polymer nanoparticle can successfully carry the photosensitizer and the chemotherapy drugs to tumor cells, and produce active oxygen during illumination, so as to realize tumor killing. Azo bonds contained in the nanoparticle can be degraded under the action of reductase in cells, and chemotherapy drug release is realized. In addition, cell hypoxia caused during a photodynamic therapy process can further improve drug release, and the hypoxia response polymer nanoparticle can properly realize excellent tumor therapy effect through combination therapy effect of photodynamic therapy and chemical therapy.
Owner:MENGCHAO HEPATOBILIARY HOSPITAL OF FUJIAN MEDICAL UNIV
Human breast cancer chronic intermittent hypoxia cell line, and preparation method thereof
InactiveCN102827811AProliferate fastImprove attack abilityMicroorganism based processesTumor/cancer cellsChronic intermittent hypoxiaStem cell line
The invention belongs to the field of microbial and animal cell lines, and relates to a human breast cancer chronic intermittent hypoxia cell line. Stable-growth human breast cancer chronic intermittent hypoxia cell strain MCF-7H is obtained by employing human breast cancer cell line MCF-7 as stem cells and by using chronic intermittent hypoxia in-vitro culture for passage. The preservation number of the cell strain MCF-7H is CGMCC No. 4902; and the classification name is human breast cancer chronic intermittent hypoxia cell strain MCF-7H. The cells show multi-polar epithelial morphological characteristics, aggregate into sheet or cluster shapes, have fast multiplication rate, strong invasion capability and up-regulated expression of regulatory pathway of a hypoxia reaction, and have tumor formation capability not significantly different from that of the stem cell line. The formed transplanted tumor has fast growth rate; and simultaneously expression of regulatory pathway of the hypoxia reaction is up-regulated continuously. The human breast cancer chronic intermittent hypoxia cell line can reproduce the human breast cancer cell line produced in a real in-vivo hypoxia environment, and is an ideal and reliable model for in-vivo and in-vitro hypoxia-related researches.
Owner:FUDAN UNIV SHANGHAI CANCER CENT
Anti-hypoxia food, health-care product or pharmaceutical composition, and preparation method and application thereof
PendingCN112617197ACompatibility is reasonableImprove oxygen resistanceOrganic active ingredientsSugar food ingredientsBiotechnologyDisease
The invention provides an anti-hypoxia food, health-care product or pharmaceutical composition, and a preparation method and application thereof. The composition is a food, health-care product or pharmaceutical preparation prepared from the following raw materials in parts by weight: 80-120 parts of rhizoma polygonati, 24-36 parts of ginseng, 16-24 parts of cordyceps militaris, 16-24 parts of spirulina maxima, 16-24 parts of chia seeds, 16-24 parts of fructus lycii, 16-24 parts of albumin peptide, 16-24 parts of oyster peptide, 16-24 parts of sea buckthorn, 12-18 parts of pollen pini and 0.1-1 part of vitamin C. The composition disclosed by the invention is reasonable in compatibility, and plays a synergistic effect on fatigue resistance and oxidation resistance; the composition can also be used for relieving altitude stress and preventing acute and chronic altitude hypoxia diseases; meanwhile, the raw materials used in the composition are safe and free of toxic and side effects; safe and efficient energy supply can be provided; the endurance capacity of an organism to an anoxic environment is enhanced; symptoms, such as an anoxic reaction of the organism, are effectively relieved; and the composition has a good application prospect.
Owner:成都藏源高能生物科技有限公司
Intracellular polymerization method for hypoxia response type alkyne-amine click polymerization and application of intracellular polymerization method
PendingCN114736938APrecise positioningIndividual particle analysisFluorescence/phosphorescenceNitro compoundNitroreductase
The invention provides an intracellular polymerization method for hypoxia response type alkyne-amine click polymerization and application of the intracellular polymerization method, and belongs to the technical field of biochemistry. The intracellular polymerization method for hypoxia response type alkyne-amine click polymerization, provided by the invention, comprises the following steps: (1) performing hypoxia culture on cells in a binary nitro compound solution; (2) transferring the cells subjected to hypoxic culture in the step (1) into a binary alkynyl compound solution for normal oxygen culture; and (3) transferring the cells subjected to the normal oxygen culture in the step (2) into a culture medium for normal oxygen culture, so as to realize intracellular polymerization of hypoxia response type alkyne-amine click polymerization. The binary nitro compound is reduced into a diamine compound through nitroreductase in a cell under the hypoxic condition, and the reduced diamine compound and a binary alkynyl compound are polymerized in the cell, so that anchoring of fluorescent small molecules is realized, a fluorescent signal is lightened, and fluorescence imaging of the cell is realized.
Owner:SOUTH CHINA UNIV OF TECH
Hypoxia response gene editing method
PendingCN112843254AGreat potentialEffective treatmentOrganic active ingredientsPeptide/protein ingredientsCarboxyl radicalTumor therapy
The invention discloses a gene editing method for hypoxia response. The nanometer composite material APACP is composed of Cas9 / sgRNA and AuNRs modified by p-carboxyl azobenzene, and the outermost layer of the nanometer composite material APACP is wrapped with a layer of polyethyleneimine PEI. According to the present invention, 4-carboxylazobenzene is subjected to specific reduction in the tumor hypoxic microenvironment, such that the azo bond is broken, such that the accurate and controllable release of Cas9 / sgRNA covalently linked to the APACP nano-particle is achieved, and the effective gene editing is achieved based on the CRISPR-Cas9 system; according to the photo-thermal conversion characteristic of AuNRs, after a target gene in tumor tissue is knocked out in Cas9 / sgHSP90, a photo-thermal therapy is used for treating tumors. Cell and animal experiments prove that the treatment method is effective and superior to AuNRs photo-thermal treatment, and the wide potential of the APACP nanoparticles in tumor treatment is also proved.
Owner:NANJING UNIV
A nanoparticle releasing hydrogen sulfide under anaerobic conditions and its preparation method and application
Owner:NANJING UNIV OF POSTS & TELECOMM
A kind of hypoxia-responsive liposome drug carrier and preparation method and application thereof
ActiveCN106692059BNo leakageSmall toxicityPharmaceutical non-active ingredientsAntineoplastic agentsNitro compoundDisease
The invention discloses a hypoxia response lipidosome drug carrier. The hypoxia response lipidosome drug carrier is prepared from phospholipid, cholesterol and hypoxia response molecules, wherein the mass ratio of the cholesterol to the phospholipid ranges from 1:10 to 1:2, and the mass ratio of the hypoxia response molecules to the phospholipid ranges from 1:10 to 1:4; the phospholipid is a mixture of dipalmitoyl phosphatidylcholine, dimyristoyl phosphatidylcholine and methoxy-polyethylene glycol-distearoyl phosphoethanolamine; the hypoxia response molecules are derivatives of a hydrophobic aromatic nitro compound and are located between bimolecular layers of the phospholipid. The hypoxia response lipidosome drug carrier disclosed by the invention is used for loading an antitumor drug, and has a remarkable effect in application to drugs for treating tumors or other hypoxia-related diseases.
Owner:北京华诺泰生物医药科技有限公司
Two-stage integrated biological nitrogen and phosphorus removal reactor
ActiveCN106986456AHigh removal rateSimultaneous nitrogen and phosphorus removalBiological treatment apparatusTreatment with aerobic and anaerobic processesEngineeringDigestion
The invention discloses a two-stage integrated biological nitrogen and phosphorus removal reactor. The reactor comprises a reactor main body. The inner chamber of the reactor main body is divided into a primary reaction zone and a secondary reaction zone through a secondary reactor in the inner chamber. The primary reaction zone is orderly divided into an anaerobic sludge discharge unit, an anaerobic reaction unit and an overflow unit from bottom to top along the axial direction of the reactor main body. The secondary reaction zone is orderly divided into an anoxic denitrification unit, a three-phase separation unit and an aerobic biofilm reaction unit from bottom to top along the axial direction of the reactor main body. A return device is arranged outside the reactor main body. The aerobic biofilm reaction unit is communicated with an anoxic reaction digestion unit through the return device. The two-stage integrated biological nitrogen and phosphorus removal reactor creates aerobic, anoxic and anaerobic alternating environments, keeps a high COD removal rate and realizes simultaneous removal of nitrogen and phosphorus. The integrated reactor saves a floor space. Residual sludge and phosphorus-rich sludge in the aerobic reaction zone can be smoothly discharged. The acid production reaction in the anaerobic reaction unit can provide acidity for the anoxic reaction unit.
Owner:HANGZHOU NORMAL UNIVERSITY
Polymer micelle material, preparation and application thereof, and targeted drug of polymer micelle material, preparation and application thereof
InactiveCN113480738AImprove the effect of anti-tumor therapyAlleviate hypoxic environmentInorganic active ingredientsPharmaceutical non-active ingredientsNitroimidazolePolymer science
The invention discloses a polymer micelle material, preparation and application thereof, and a targeted drug of the polymer micelle material, preparation and application thereof, wherein the polymer micelle material has a chemical formula as shown in a formula (1). According to the invention, the polymer micelle material is grafted with a nitroimidazole hypoxia response group on a side chain, and surface glucose target molecule modification is further carried out in some specific embodiments, so that the polymer micelle material not only has the performance of actively targeting tumors, but also has hypoxic microenvironment response, can release drugs in a hypoxic microenvironment, and realizes efficient drug delivery and tumor treatment.
Owner:SICHUAN UNIV
Synthesis method and application of hypoxia response type ratio probe
ActiveCN113984729AHigh sensitivityStrong specificityMaterial nanotechnologyNanomedicineDendrimerNitroreductase
The invention belongs to the field of biological analysis, particularly relates to a synthesis method and application of a hypoxia response type ratio probe, and aims to solve the problem that the hypoxia degree cannot be accurately and reliably evaluated since only qualitative hypoxia detection can be realized in the conventional hypoxia imaging of a living body. The synthesis method comprises the following steps: modifying a fifth generation of polyamide-amine dendrimer PAMAMG5 by adopting an anthocyanin fluorescent dye Cy5-NHS to obtain PG5-Cy5; encapsulating a nitroreductase response type fluorescent molecule Cy7-NO2 in a hydrophobic cavity of PG5-Cy5 to form Cy7-NO2 / PG5-Cy5; and modifying the outer layer of the Cy7-NO2 / PG5-Cy5 with oligo-hyaluronic acid (LWHA) selected as a tumor recognition group, and synthesizing the Cy7-NO2 / PG5-Cy5@LWHA. The hypoxia response type ratio probe prepared by the invention has the characteristics of high sensitivity, high specificity and long in-vivo circulation.
Owner:INST OF AUTOMATION CHINESE ACAD OF SCI
A hypoxia-responsive co-assembly system based on extracellular vesicles and preparation method thereof
ActiveCN113831911BEfficient enrichmentLuminescence/biological staining preparationMaterial analysis by optical meansExtracellular vesicleAluminum phthalocyanine
The present disclosure relates to a co-assembly system for hypoxia response imaging based on extracellular vesicles, the co-assembly system comprising extracellular vesicles and Pc / C5A attached to the extracellular vesicles, the Pc / C5A contains calixarene QAC5A‑6C and aluminum phthalocyanine AlPcS 4 ; the calixarene QAC5A-6C (C5A) and aluminum phthalocyanine AlPcS 4 (Pc) A first incubation mixed and performed yields Pc / C5A; a second incubation mixed with extracellular vesicles results in a co-assembled system for hypoxia-responsive imaging.
Owner:NANKAI UNIV
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com